The pathophysiology of acute graft-versus-host disease

被引:171
|
作者
Ferrara, JLM [1 ]
Cooke, KR [1 ]
Teshima, T [1 ]
机构
[1] Univ Michigan, Ctr Canc, Bone Marrow Transplant Program, Ann Arbor, MI 48109 USA
关键词
bone marrow transplantation; graft-versus-host disease; cytokines; TNF-alpha; IL-1; beta;
D O I
10.1007/BF02983793
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The pathophysiology of acute graft-versus-host disease (GVHD) is a complex process that can be conceptualized in three phases. In the first phase, high-dose chemoradiotherapy causes damage to host tissues, including a self-limited burst of inflammatory cytokines such as tumor necrosis factor (TNF)-alpha and interleukin 1. These cytokines activate host antigen-presenting cells (APCs). In the second phase, donor T-cells recognize alloantigens on host APCs. These activated T-cells then proliferate, differentiate into effector cells, and secrete cytokines, particularly interferon (IFN)-gamma. In the third phase, target cells undergo apoptosis mediated by cellular effectors (eg, donor cytotoxic T-lymphocytes) and inflammatory cytokines such as TNF-alpha. TNF-alpha. secretion is amplified by stimuli such as endotoxin that leaks across damaged gastrointestinal mucosa injured by the chemoradiotherapy in the first phase. TNF-alpha and IFN-gamma cause further injury to gastrointestinal epithelium, causing more endotoxin leakage and establishing a positive inflammatory feedback loop. These events are examined in detail in the following review. Int J Hematol. 2003;78:181-187. (C)2003 The Japanese Society of Hematology.
引用
收藏
页码:181 / 187
页数:7
相关论文
共 50 条
  • [41] A biomarker panel for acute graft-versus-host disease
    Paczesny, Sophie
    Krijanovski, Oleg I.
    Braun, Thomas M.
    Choi, Sung W.
    Clouthier, Shawn G.
    Kuick, Rork
    Misek, David E.
    Cooke, Kenneth R.
    Kitko, Carrie L.
    Weyand, Angela
    Bickley, Daniel
    Jones, Dawn
    Whitfield, Joel
    Reddy, Pavan
    Levine, John E.
    Hanash, Samir M.
    Ferrara, James L. M.
    BLOOD, 2009, 113 (02) : 273 - 278
  • [42] Cytokine cascades in acute graft-versus-host disease
    Krenger, W
    Hill, GR
    Ferrara, JLM
    TRANSPLANTATION, 1997, 64 (04) : 553 - 558
  • [43] Resolution of acute intestinal graft-versus-host disease
    Sindhu Thiagarajan
    Markus F. Neurath
    Kai Hildner
    Seminars in Immunopathology, 2019, 41 : 655 - 664
  • [44] Cytokines and costimulation in acute graft-versus-host disease
    Hill, Geoffrey R.
    Koyama, Motoko
    BLOOD, 2020, 136 (04) : 418 - 428
  • [45] Management of Acute Graft-Versus-Host Disease in Children
    Carpenter, Paul A.
    MacMillan, Margaret L.
    PEDIATRIC CLINICS OF NORTH AMERICA, 2010, 57 (01) : 273 - +
  • [46] Prophylaxis and treatment of acute graft-versus-host disease
    Chao, NJ
    Chen, BJ
    SEMINARS IN HEMATOLOGY, 2006, 43 (01) : 32 - 41
  • [47] Acute graft-versus-host disease in the small intestine
    Watanabe, N
    Okazaki, K
    Yazumi, S
    Nishi, T
    Matsuura, M
    Chiba, T
    GASTROINTESTINAL ENDOSCOPY, 2002, 55 (06) : 716 - 716
  • [48] PREVENTION AND TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE
    HERVE, P
    PRESSE MEDICALE, 1991, 20 (33): : 1614 - 1621
  • [49] Emerging drugs for acute graft-versus-host disease
    Khaled, Yasser
    Reddy, Pavan
    Krijanovski, Oleg
    EXPERT OPINION ON EMERGING DRUGS, 2009, 14 (02) : 219 - 232
  • [50] PREVENTION AND TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE
    NEUDORF, S
    FILIPOVICH, A
    RAMSAY, N
    KERSEY, J
    SEMINARS IN HEMATOLOGY, 1984, 21 (02) : 91 - 100